PRESIDENT
Michael G. Palfreyman, Ph.D., D.Sc.
Michael G. Palfreyman is a seasoned leader specializing in drug discovery and development, translational R&D and early clinical proof of concept for the biotechnology and pharmaceutical industries. Dr. Palfreyman has over 40 years’ experience in leadership roles, including vice president, chairman of the board, chief scientific officer, senior scientific advisor, R&D diligence, translational R&D, scientific advising, program management, and product development. He is currently Chairman and CEO for C-Click Life Sciences, Inc., a Partner at MindMerge Advisors, Inc., on the Scientific Advisory Board of Brenig Therapeutics, and has been elected as a non-executive director at N4Pharma. Companies and clients include Cybin, Inc., Marion Merrell Dow (Sanofi Aventis), Scriptgen (Anadys) Pharmaceuticals, EnVivo (Forum) Pharmaceuticals, Amakem Therapeutics, and Aminex Therapeutics, and more. Dr. Palfreyman has been an invited speaker and chairperson for several international and national conferences, is co-inventor on 53 issued US patents, 12 pending patents and co-author of over 150 scientific articles and book chapters. View list of publications, citations, and patents.
ADVISOR
Brett J. Greene
Former Chief Innovation Officer at Cybin Inc. and co-founder/President/Chief Strategy Officer at Adelia Therapeutics (acquired by Cybin in 2020), Brett brings decades of experience in psychedelic and cannabinoid-based drug discovery and development.
Previously, he served as a research administrator at Northeastern University’s Center for Drug Discovery, contributing to groundbreaking advancements in the field.
Brett’s leadership and strategic insights have been pivotal in shaping innovative therapies and guiding companies through successful acquisitions.
ADVISOR
Alex Nivorozhkin
Dr. Nivorozhkin is a seasoned medicinal chemist, drug delivery expert and founder of multiple biotech companies. He is a NCE inventor of multiple successfully partnered drug discovery and development programs and technology developer of the proprietary formulations for CNS drugs. He was a founder of Adelia Therapeutics acquired by Cybin, Inc. (NYSE:CYBN) in 2020 where he continues to serve as Chief Scientific Officer. He is a co-inventor on over 100 issued and pending patents and co-authored over 70 peer-reviewed publications.
COMMUNICATIONS
Lois E. Slavin, M.S.
Throughout her career, Lois Slavin worked extensively in strategic branding, most recently at the Massachusetts Institute of Technology. There she also created and hosted a webinar series featuring MIT professors and students speaking on how to address interdisciplinary challenges in new product development. She has written extensively on this topic, as well as the competitive advantage of engaging diverse and interdisciplinary teams. She has taught media-related courses at Harvard, Emerson College and Boston University, as well as privately in Tehran.
